title: A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
abstract: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first drug approved in this group in 2013 and subsequently dapagliflozin was approved in January 2014 and empagliflozin was approved in August 2014. Preclinical studies have demonstrated safety, tolerability, and efficacy in terms of glycemic control and HbA1c level in type 2 diabetes mellitus (T2DM) patients in comparison to other anti-diabetic drugs. The U.S. Food and Drug Administration (FDA) recently released a warning that some of the patients who used SGLT2 inhibitors developed diabetic ketoacidosis (DKA). Empagliflozin has showed safety in type 2 diabetics with renal impairment. Each of these medications can be used as a single treatment or in combination with other anti-diabetic medications.
authors.affiliation: TTUHSC Paul L Foster - Internal Medicine El Paso, TX, United States.
authors.forename: Saad Hussain
authors.initials: SH
authors.lastname: Syed
authors.forename: Sucheta
authors.initials: S
authors.lastname: Gosavi
authors.forename: Waseem
authors.initials: W
authors.lastname: Shami
authors.forename: Marco
authors.initials: M
authors.lastname: Bustamante
authors.forename: Zul
authors.initials: Z
authors.lastname: Farah
authors.forename: Muhammad
authors.initials: M
authors.lastname: Teleb
authors.forename: Aamer
authors.initials: A
authors.lastname: Abbas
authors.forename: Sarmad
authors.initials: S
authors.lastname: Said
authors.forename: Debabrata
authors.initials: D
authors.lastname: Mukherjee
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000068896:Canagliflozin / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014481:United States; D015431:Weight Loss
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin; C529054:dapagliflozin; C570240:empagliflozin